Results 11 to 20 of about 798,539 (256)
Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation [PDF]
Antibodies, 2019 Therapeutic antibody technology heavily dominates the biologics market and continues to present as a significant industrial interest in developing novel and improved antibody treatment strategies.
Vicki Sifniotis +3 more
doaj +2 more sources
Antibody Profiling: Kinetics with Native Biomarkers for Diagnostic Assay and Drug Developments
Biosensors, 2023 Despite remarkable progress in applied Surface Plasmon Resonance (SPR)-based methods, concise monitoring of kinetic properties for native biomarkers from patient samples is still lacking.
Ute Jucknischke +4 more
doaj +1 more source
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Cell Reports, 2022 Summary: The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with the ability to escape existing humoral protection conferred by previous infection and/or immunization necessitates the discovery of broadly ...
Shiho Tanaka +14 more
doaj +1 more source
Ensembles in solution as a new paradigm for antibody structure prediction and design
mAbs, 2021 The rise of antibodies as a promising and rapidly growing class of biotherapeutic proteins has motivated numerous studies to characterize and understand antibody structures.
Monica L. Fernández-Quintero +3 more
doaj +1 more source
Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
Frontiers in Molecular Biosciences, 2022 As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy.
Monica L. Fernández-Quintero +11 more
doaj +1 more source
Antibodies, 2023 T cell receptor β-chain constant (TRBC) is a promising class of cancer targets consisting of two highly homologous proteins, TRBC1 and TRBC2. Developing targeted antibody therapeutics against TRBC1 or TRBC2 is expected to eradicate the malignant T cells ...
Xincheng Zeng +4 more
doaj +1 more source
Frontiers in Immunology, 2022 Single-domain antibodies (sdAbs) are a promising class of biotherapeutics with unique structural traits within their paratope region. The distribution of canonical conformations explored by their complementarity determining region (CDR) loops differs to ...
Francis Gaudreault +3 more
doaj +1 more source
Communications Biology, 2021 Lu Shan et al. present a structure-guided approach to engineer a monovalent form of the fragment crystallizable (Fc) region of an IgG4 antibody to adapt multiple versions of half-life extension modifications and bispecific targeting.
Lu Shan +12 more
doaj +1 more source
Frontiers in Immunology, 2023 Antibodies, through their ability to target virtually any epitope, play a key role in driving the adaptive immune response in jawed vertebrates. The binding domains of standard antibodies are their variable light (VL) and heavy (VH) domains, both of ...
Bora Guloglu +3 more
doaj +1 more source
Conformational Entropy as a Potential Liability of Computationally Designed Antibodies
Biomolecules, 2022 In silico antibody discovery is emerging as a viable alternative to traditional in vivo and in vitro approaches. Many challenges, however, remain open to enabling the properties of designed antibodies to match those produced by the immune system. A major
Thomas Löhr +2 more
doaj +1 more source